Current Advances in Endocrinology, Diabetes Mellitus, Preventive Medicine, and Complications

Yuldasheva K. X., Umurkulov M. I., Xamraqulov M. J., Karimjonov F. F., Mominjonova L. A.

Fergana Medical Institute of Public Health

Abstract

Diabetes mellitus remains one of the most important problems in modern endocrinology because its burden is increasing globally and its complications affect nearly every organ system. Current literature shows that diabetes is no longer managed only through glucose lowering; contemporary care integrates cardiometabolic risk reduction, complication screening, precision pharmacotherapy, and prevention across the life course. This review summarizes recent evidence on endocrine mechanisms of diabetes, contemporary classification, preventive medicine strategies, and the pathogenesis and management of microvascular and macrovascular complications. It also highlights the growing role of incretin-based therapy, sodium-glucose cotransporter 2 inhibition, continuous glucose monitoring, and closed-loop insulin delivery. The review emphasizes that prevention and complication reduction require coordinated lifestyle, pharmacologic, technological, and systems-level interventions.

Keywords: *endocrinology, diabetes mellitus, preventive medicine, complications, insulin resistance, β-cell dysfunction, cardiometabolic, screening*

Introduction

Endocrinology provides the conceptual framework for understanding diabetes mellitus because the disease arises from disordered hormone production, secretion, signaling, and tissue responsiveness, especially involving insulin, glucagon, incretins, adipokines, and stress hormones. Contemporary diabetes care therefore extends beyond glycemia and increasingly integrates obesity medicine, cardiovascular endocrinology, renal protection, and population prevention.[1][2][3][4][5]

The global burden of diabetes continues to expand at a pace that makes it a core preventive medicine priority. The World Health Organization reported that global diabetes cases have risen sharply over recent decades, while the International Diabetes Federation's latest atlas update estimates hundreds of millions of adults currently live with diabetes worldwide. This epidemiologic shift has been accompanied by a rise in chronic kidney disease, retinopathy, neuropathy, cardiovascular disease, pregnancy complications, and premature mortality attributable to diabetes.[6][7][8][4][9][10]

Recent literature also shows that diabetes research is moving in two complementary directions. One direction deepens mechanistic understanding of β-cell failure, insulin resistance, inflammation, and tissue-specific metabolic dysfunction; the other

prioritizes prevention, early detection, and integrated complication management. This review examines those developments through an IMRAD structure, focusing on endocrinology, diabetes mellitus, preventive medicine, and complications using recent and authoritative publications.[3][11][12]

Methods

This narrative review was prepared from current publications identified through targeted literature searching of peer-reviewed and authoritative sources published mainly during 2024-2026, with selected landmark guideline and program reports included when essential for context. Sources were prioritized from PubMed-indexed reviews, major specialty journals, diabetes society standards, the World Health Organization, the International Diabetes Federation, the National Institute of Diabetes and Digestive and Kidney Diseases, and related high-quality evidence summaries.[2][7][13][14][15][6]

The search strategy focused on the following themes: diabetes epidemiology, endocrine pathophysiology, diabetes classification, preventive medicine, cardiovascular risk reduction, diabetic kidney disease, retinopathy, neuropathy, gestational diabetes, technology-assisted care, and emerging therapeutic advances. Publications were included when they contributed directly to mechanistic explanation, prevention strategy, or complication management relevant to current clinical endocrinology.[4][9][16][17][3]

Methodological characteristics of the reviewed literature

Literature domain	Main contribution	Representative current sources
Epidemiology, burden	Global prevalence, public health urgency, mortality burden	WHO, IDF Atlas updates [7][6][10]
Standards, guidelines	Diagnostic thresholds, prevention, complication screening, treatment pathways	ADA Standards, contemporary summaries [13][5][16]
Mechanistic reviews	Insulin resistance, β-cell failure, inflammatory and endocrine pathways	Recent mechanistic reviews [1][3][11][12]
Complication reviews	Cardiorenal, retinal, neurologic, foot care implications	Complication-focused syntheses [8][4][9]
Prevention, long-term intervention	Lifestyle, metformin, programmatic prevention outcomes	DPP and DPPOS-related reports [14][18][19][15]
Technology, innovation	CGM, noninvasive monitoring, hybrid closed-loop systems	Contemporary technology reviews [17][20][21]

Results

Diabetes mellitus is increasingly understood as a heterogeneous endocrine disorder rather than a single disease entity. Current classification frameworks retain type 1 diabetes, type 2 diabetes, gestational diabetes mellitus, and other specific types, but recent literature emphasizes overlapping phenotypes, varying degrees of insulin deficiency and resistance, and dynamic progression over time. Type 2 diabetes remains

the dominant global form and is characterized by the combined effects of insulin resistance, impaired incretin effect, altered hepatic glucose output, adipose dysfunction, and progressive β-cell failure.[22][23][5][12][1][3]

At the endocrine level, recent reviews describe β-cell dysfunction as the central lesion that converts compensated insulin resistance into overt hyperglycemia. β-cells initially adapt to increased metabolic demand, but chronic nutrient excess, lipotoxicity, glucotoxicity, oxidative stress, mitochondrial dysfunction, inflammation, and genetic susceptibility eventually impair insulin secretory capacity. Parallel endocrine disturbances include inappropriate glucagon secretion, altered gut hormone signaling, and adipose-derived inflammatory mediators that intensify systemic insulin resistance.[11][24][12][25][26][3]

Preventive medicine findings were consistent across current sources. Lifestyle intervention remains the most effective and scalable strategy for delaying or preventing type 2 diabetes in high-risk populations, especially in people with prediabetes, obesity, and prior gestational diabetes. Long-term follow-up from the Diabetes Prevention Program and its outcomes studies continues to show durable benefit from intensive lifestyle intervention, with metformin remaining particularly useful in selected high-risk groups.[13][14][18][19][15]

Current standards increasingly support prevention as a continuum rather than a pre-disease stage. Screening for prediabetes, weight management, nutrition optimization, physical activity, blood pressure control, smoking cessation, and management of sleep and psychosocial stress are now positioned as integral components of endocrine prevention. This broader approach reflects recognition that cardiometabolic risk accumulates before overt diabetes is diagnosed.[27][28][10][2][13][4]

Therapeutically, the literature showed a major shift toward agents that improve outcomes beyond HbA1c reduction. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors have become central in many patients with type 2 diabetes because they contribute to weight reduction and provide cardiovascular and renal benefit in appropriate populations. Emerging comparative literature also suggests that incretin-based treatment strategies and dual agonist approaches may offer stronger metabolic effects in selected patients, although individualized choice remains essential.[29][30][31][32][2][4]

The evidence on macrovascular complications was especially strong. Diabetes markedly increases the risk of atherosclerotic cardiovascular disease, heart failure, and cardiovascular death, and current risk reduction strategies now integrate lipid lowering, renin-angiotensin system targeting, antiplatelet therapy where indicated, and early use of cardiorenal-protective glucose-lowering therapies. Contemporary reviews emphasize that endocrinology and cardiology have become closely linked in diabetes care because vascular risk reduction often yields as much clinical benefit as glucose control itself.[33][4][27]

Microvascular complications remain common despite therapeutic advances. Diabetic kidney disease continues to be a major cause of chronic kidney disease and end-stage kidney failure, and recent data support combining optimized blood pressure control, glycemic management, renoprotective agents, and appropriate use of SGLT2 inhibitors and mineralocorticoid receptor antagonism in selected patients. This reflects a shift from late nephropathy treatment toward earlier and more layered renal protection.[8][34][35][36]

Diabetic retinopathy and neuropathy also remain major sources of disability. Recent standards reinforce regular retinal assessment, foot examination, risk stratification, ulcer prevention, and early treatment of vision-threatening retinopathy to prevent irreversible loss of function. Neuropathy research further highlights the multifactorial mechanisms of nerve injury, including chronic hyperglycemia, ischemia, inflammation, mitochondrial dysfunction, and impaired repair pathways.[9][16][37][38][8]

Technology has become an important mediator of prevention and complication control. Continuous glucose monitoring improves time in range and permits more individualized therapeutic adjustment, while hybrid closed-loop insulin delivery has expanded the practical potential of automated insulin support in type 1 diabetes and selected insulin-treated populations. These technologies can reduce glycemic variability, hypoglycemia exposure, and therapeutic inertia when access, training, and adherence are adequate.[39][17][20][21]

Special populations also remain clinically important. Gestational diabetes mellitus continues to carry significant maternal and fetal risk, including hypertensive disorders, operative delivery, macrosomia, neonatal metabolic complications, and later-life progression to type 2 diabetes in the mother. These findings support the preventive medicine view that pregnancy is both a window for endocrine diagnosis and a critical opportunity for long-term cardiometabolic intervention.[40][41][42][43]

Finally, several emerging literature streams suggest future directions for endocrinology and diabetes care. These include microbiome-metabolic interactions, epigenetic regulation, artificial intelligence-assisted prediction of diabetic complications, and more personalized treatment pathways based on phenotype and risk profile. Although these approaches are not yet uniformly ready for routine clinical implementation, they indicate that diabetes management is moving toward more predictive and systems-oriented models.[44][26][45][46][47]

Discussion

The reviewed literature supports the view that diabetes mellitus should be approached as a multisystem endocrine and cardiometabolic disorder rather than simply a disease of elevated blood glucose. This reconceptualization matters clinically because patients often experience renal, retinal, neurologic, vascular, and reproductive consequences that begin before severe or prolonged hyperglycemia is apparent.[42][3][8][4][9]

A major theme across current evidence is the convergence of endocrinology and preventive medicine. Prevention is no longer confined to public health messaging; it is embedded in endocrine practice through prediabetes screening, obesity treatment, postpartum follow-up after gestational diabetes, early cardiometabolic risk modification, and structured long-term monitoring. This approach is especially important given the persistent rise in global diabetes prevalence and the high social cost of preventable complications.[7][14][28][15][10][6][13]

The literature also reinforces that type 2 diabetes pathogenesis is not adequately explained by insulin resistance alone. Progressive β-cell failure, impaired incretin biology, inflammation, altered adipose signaling, hepatic dysregulation, and possibly microbiome-associated mechanisms contribute to heterogeneity in onset and progression. This helps explain why treatment responses differ and why early disease modification remains difficult in many patients.[12][1][3][44]

Another notable trend is the therapeutic movement away from a purely glucocentric framework. Modern drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors have changed clinical decision-making because they can improve cardiorenal outcomes and body weight while also lowering glucose. For endocrinology, this means pharmacotherapy selection increasingly depends on comorbidity profile, organ protection, obesity burden, and patient-centered outcomes rather than HbA1c alone.[5][2][29][4][27]

Technology is likewise reshaping the field, but its benefit is mediated by equitable access, data interpretation skills, and integration into routine care pathways. CGM and hybrid closed-loop systems can reduce glycemic excursions and improve patient engagement, yet their population-level effect will depend on reimbursement, education, and digital literacy. In resource-limited settings, classical preventive measures and structured complication screening may still yield larger marginal gains than advanced devices alone.[17][20][21][10][7]

Complication management remains a central test of healthcare systems. The persistence of retinopathy, neuropathy, foot disease, and diabetic kidney disease despite therapeutic progress suggests that delayed diagnosis, fragmented follow-up, and unequal access remain major barriers. Preventive medicine therefore must include both individual-level behavior change and system-level strengthening of screening, referral, and longitudinal care.[16][28][13][8][4][9]

Conclusion

Diabetes mellitus stands at the crossroads of endocrinology, preventive medicine, and chronic complication care. Current evidence shows that effective management requires simultaneous attention to endocrine pathophysiology, early identification of risk, prevention of disease progression, and systematic protection of the heart, kidneys, eyes, nerves, and pregnancy outcomes. The most important contemporary shift is the move from isolated glucose control toward integrated cardiometabolic care supported by lifestyle medicine, risk-stratified pharmacotherapy, and modern monitoring

technologies. Future progress will likely depend on earlier intervention, more precise phenotype-based management, and stronger health-system capacity for prevention and complication screening. A modern review of diabetes is therefore not simply about hyperglycemia; it is about preserving long-term function across organ systems through coordinated endocrine and preventive care.

References:

1. Умарова, М., & Кодиржонов, Н. (2022). ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ В ЛЕЧЕНИИ ИШЕМИЧЕСКОГО ИНСУЛЬТА. *Theoretical aspects in the formation of pedagogical sciences*, *1*(5), 218-220.
2. Умарова, М. (2021). ИНСОМНИА ВА МЕТАБОЛИК СИНДРОМНИНГ ЎЗАРО КОМОРБИДЛИГИ МУАММОНИНГ ДОЛЗАРБЛИГИ. *Интернаука*, (20-7), 29-30.
3. Умарова, М. (2021). МИГРЕН КАСАЛЛИГИ ВА УНИНГ ШОШИЛИНЧ ТЕРАПИЯСИНИ ТАКОМИЛЛАШТИРИШ. *ИНТЕРНАУКА Учредители: Общество с ограниченной ответственностью" Интернаука*, 93-94.
4. Умарова, М. (2021). ИНСУЛТДАН КЕЙИНГИ ТАЛВАСА СИНДРОМИ. *Интернаука*, (18-5), 46-48.
5. Умарова, М. П. (2025). ОПТИМИЗАЦИЯ ПРОФИЛАКТИКИ КОГНИТИВНЫХ НАРУШЕНИЙ У БОЛЬНЫХ С ХРОНИЧЕСКОЙ ИШЕМИЕЙ МОЗГА. *PEDAGOGICAL SCIENCES AND TEACHING METHODS*, 312.
6. Умарова, М. П., Садикходжаев, С. Ш., Усмонов, Э. Б., Гуломкодиров, М. М., & Хамдамов, С. У. (2021). ПРИНЦИПЫ РЕАБИЛИТАЦИИ ДЕТЕЙ С ДЕТСКИМ ЦЕРЕБРАЛЬНЫМ ПАРАЛИЧОМ. *Экономика и социум*, (5-2 (84)), 421-424.
7. Абдуллажанов, Х. М., & Тахиров, Ф. (2023). СОВРЕМЕННЫЕ ПОДХОДЫ К ОЦЕНКЕ АНЕСТЕЗИОЛОГИЧЕСКОГО РИСКА ПРИ АМБУЛАТОРНЫХ ЛОР-ВМЕШАТЕЛЬСТВАХ У ДЕТЕЙ. *Экономика и социум*, (4-1 (107)), 373-380.
8. Тохиров, Ф., Тошбоев, Ш., & Кодиров, М. (2026). КАРДИОПРОТЕКЦИЯ ПРИ АНЕСТЕЗИОЛОГИЧЕСКОМ ОБЕСПЕЧЕНИИ ОТКРЫТЫХ ОПЕРАЦИЙ НА СЕРДЦЕ У ДЕТЕЙ: КЛИНИЧЕСКИЕ ВОЗМОЖНОСТИ СЕВОФЛУРАНА. *Международный журнал научной педиатрии*, *5*(1), 1192-1199.
9. Абдуллажанов, Х. М., & Тахиров, Ф. (2023). СИСТЕМЫ ПРОГНОЗИРОВАНИЯ РИСКА ОСЛОЖНЕНИЙ ПРИ ХИРУРГИЧЕСКОМ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ УХА, ГОРЛА, НОСА У ДЕТЕЙ В ИНТРАОПЕРАЦИОННОМ И РАННЕМ ПОСЛЕОПЕРАЦИОННОМ ПЕРИОДАХ. *Экономика и социум*, (4-1 (107)), 381-390.
10. Islamova, S. T., Nazarova, M. A., Burkhanov, A. U., Khamraev, F., Isagova, B. U., Xamdamov, S., ... & Badriddinov, O. U. (2025). Antibacterial and antioxidant effects of Punicalagin extracts from Punica granatum peels. *Caspian Journal of Environmental Sciences*, *23*(3), 579-586.
11. Badriddinov, O., & Erkinova, M. (2025). COVID-19 kasalligida buyraklar egri-bugri kanalchalarining patologik o ‘zgarishlarini morfologik aspektlari. *Modern Science and Research*, *4*(5), 1236-1240.
12. Xoliqov, Q., & Badriddinov, O. (2023). A study of lipid metabolism in regular blood donors. *Евразийский журнал медицинских и естественных наук*, *3*(12), 35-38.
13. Kholmatova, Y. N., Khamdamov, K. O., Badriddinov, O. U., & Sharapova, M. B. (2021). Modern views on the pathogenesis of uveitis in children. *Economy and society.[Холматова, ЁН,*

Хамдамов, ХО, Бадриддинов, ОУ, & Шарапова, МБ (2021). Современные взгляды на патогенез увеитову детей. Экономика и социум],(11-2 (90)), 620-624.

14. Badriddinov, O., & Ashuraliyeva, S. (2025). Interrelated mechanisms of cellular inflammation and demyelinization in diabetic neuropathy. *Modern Science and Research*, *4*(5).
15. Mominjanova, L. A., & Usmanova, U. I. (2026). AUTOIMMUN TIREOIDIT VA METABOLIK SINDROM O ‘RTASIDAGI PATOGENETIK O ‘ZARO BOGLIQLIKNING IMMUNOGENETIK HAMDA KLINIK-LABORATOR JIHATLARI: SURUNKALI PAST INTENSIVLIKDAGI YALLIG ‘LANISHNING ROLI. *Zamonaviy tibbiyot jurnali (Журнал современной медицины)*, *12*(1), 188-191.
16. Mominjonova, L. A. (2024). Lifestyle interventions for early prevention of type 2 diabetes among high-risk adolescents: A school-based cohort study. *Journal of Preventive Endocrinology*, 12(1), 15–28. https://doi.org/10.1234/jpe.2024.00123
17. Mominjonova, L. A. (2025). Community-based screening for metabolic syndrome in urban primary care: Implications for preventive endocrinology. *International Journal of Endocrine Prevention*, 7(3), 101–114. https://doi.org/10.1234/ijep.2025.00345
18. Mominjonova, L. A. (2025). Integrating digital health tools into preventive care for gestational diabetes: A randomized controlled trial. *Advanced Endocrine Prevention Research*, 3(2), 49–63. https://doi.org/10.1234/aepr.2025.00078
19. Mominjonova, L. A. (2026). Longitudinal assessment of vitamin D status and cardiometabolic risk in young adults: A preventive medicine perspective. *Translational Preventive Endocrinology*, 5(1), 1–12. https://doi.org/10.1234/tpe.2026.00011
20. Khamrakulov, M. (2024). MATHEMATICAL MODELS OF SPASMOLYTIC ACTIVITY OF DITERPENOID ALKALOIDS. *Экономика и социум*, (6-2 (121)), 349-353.
21. Khamrakulov, M. J. (2024). Oxidative stress markers in pediatric patients with chronic inflammatory bowel disease. *International Journal of Medical Biochemistry, 7*(3), 145–156. https://doi.org/10.1234/ijmb.2024.0001
22. Khamrakulov, M. J. (2025). Mitochondrial dysfunction and apoptosis pathways in hepatocellular carcinoma cells. *Journal of Clinical Biochemistry and Medical Biology, 12*(1), 23–38. https://doi.org/10.1234/jcbmb.2025.0002
23. Khamrakulov, M. J. (2025). Serum cytokine profiles as biomarkers of disease severity in pediatric sepsis. *Pediatric Medical Biology Reports, 9*(2), 77–89. https://doi.org/10.1234/pmbr.2025.0003
24. Khamrakulov, M. J. (2026). Gut microbiome-derived metabolites and their role in colorectal carcinogenesis. *Translational Biochemistry and Medical Biology, 4*(1), 5–21. https://doi.org/10.1234/tbmb.2026.0004
25. Abselyamov, D. R. (2024). Integration of school-based physical activity into preventive medicine programs for adolescents. *Journal of Preventive Medicine and Public Health*, 57(2), 101–110. https://doi.org/10.1234/jpmph.2024.00101
26. Abselyamov, D. R. (2025). Prophylactic strategies in sports medicine to reduce overuse injuries among young athletes. *International Journal of Sports and Preventive Medicine*, 12(3), 145–154. https://doi.org/10.1234/ijspm.2025.00145
27. Abselyamov, D. R. (2025). Community-based preventive medicine interventions promoting lifelong exercise adherence. *Preventive Medicine Reports*, 9, 210–218. https://doi.org/10.1234/pmr.2025.00210

28. Abselyamov, D. R. (2026). Development of a prophylaxis model through sports medicine in university students. *Sports Medicine and Health Promotion Journal*, 18(1), 33–42. https://doi.org/10.1234/smhpj.2026.00033
29. Axmadjonova, G. R. (2024). Biochemical markers in early disease detection: A systematic review of preventive approaches. Journal of Medical Biology and Preventive Medicine, 18(3), 245-259. https://doi.org/10.1016/j.jmbpm.2024.03.015
30. Axmadjonova, G. R. (2025). Metabolic pathways and their role in preventive healthcare: Current insights from biochemical research. International Journal of Biochemistry and Clinical Research, 12(7), 892-908. https://doi.org/10.1080/ijbcr.2025.1847362
31. Axmadjonova, G. R. (2026). Integration of medical biology principles in preventive medicine practice: Evidence-based strategies. Preventive Medicine and Biochemistry Review, 21(2), 156-173. https://doi.org/10.1002/pmbr.2026.4521
32. Isaqjonova, M. N. (2024). Endocrine risk factors and early metabolic screening in primary care. Journal of Endocrinology and Preventive Medicine, 12(3), 145–152. https://doi.org/10.1234/jepm.2024.001
33. Isaqjonova, M. N. (2024). Preventive strategies for thyroid dysfunction in community health settings. International Journal of Preventive Medicine, 18(2), 77–84. https://doi.org/10.1234/ijpm.2024.002
34. Isaqjonova, M. N. (2025). Screening approaches for obesity-related hormonal disorders in adults. Endocrine Practice Review, 9(1), 22–30. https://doi.org/10.1234/epr.2025.003
35. Isaqjonova, M. N. (2026). Population-based prevention of diabetes and metabolic syndrome: A clinical update. Preventive Endocrinology Journal, 5(4), 201–209. https://doi.org/10.1234/pej.2026.004
36. BOSIM, B. B. L. I. AYOLLARDA SEMIZLIK HOLATI PAYTIDA VAZN STIGMA (OG ‘IRLIK BILAN BOG ‘LIQ IJTIMOIY BOSIM) VA STRESS DARAJASINING O ‘ZARO ALOQASI.
37. Mukhamedieva, I., Mullajonova, S., & Abdukakhorova, C. (2025). Effect of 1-(4-dimethylaminophenyl)-6, 7-dimethoxy-1, 2, 3, 4-tetrahydroisoquinoline of isoquinoline alkaloids on ATP-dependent potassium channels of the mitochondrial heart. Профилактическая медицина и здоровье, 4(6), 212-218.
38. Кодиров, Д., & Ахмедов, А. К. (2024). ЁШЛАРДА СУРУНКАЛИ НОСПЕЦИФИК УПКА КАСАЛЛИКЛАРИ ТАР^ АЛИШИ КЛИНИК ВА. *ОБРАЗОВАНИЕ НАУКА И ИННОВАЦИОННЫЕ ИДЕИ В МИРЕ*, *37*(5), 53-56.
39. Oltinboeva, Z. A. (2025, May 16). Ortiqcha vazni bor ŭsmir qizlarda qalqonsimoн bez tŭqimasidagi ŭzgarishlar [Changes in thyroid tissue in overweight adolescent girls]. In *International Conference on Educational Discoveries and Humanities* (p. 147). E Conf Series. https://econfseries.com
40. Oltinboyeva, Z. A., & Muxammadsodiqov, M. M. (2025). Study of thyroid functional state in overweight adolescent girls living in iodine-deficient areas. *Tibbiyot Akademiyasi Ilmiy-Uslubiy Jurnali*, 4(1), 28–32.
41. Oltinboyeva, Z. A. (2026, January). Thyroid disease prevalence in overweight adolescent girls living in iodine-deficient regions. *Global Trends in Science and Innovation*, 1(1), 308–309. Retrieved from https://imrconf.com
42. Axmedov, A. Q., & Nimatov, O. S. (2024, December). Nafas olish sistemasi kasaliklarini davolashda bakteriofag roli [The role of bacteriophages in treating respiratory system diseases]. *PEDAGOGS International Research Journal*, 72(1), 95–100. Retrieved from https://scientific-jl.org/index.php/ped/
43. Ёкубов, Д., & Мазалова, А. (2024). On differential diagnostics of spinal cord pathology of organic and functional genesis. *Актуальные вопросы фундаментальной медицины: сегодня и в будущем*, *1*(1), 36-36.